Treatment
HYPERSENSITIVITY REACTIONS, COLD, SOLID TUMORS, HYPERSENSITIVITY REACTION
Patients in cohort Q2W-LD received escalating LDs of tusamitamab ravtansine by intravenous infusion on day 1, cycle 1, followed by the MTD as determined in the main dose-expansion cohort (100 mg/mDose-escalation schematic for the entire phase I dose-escalation study in patients with advanced solid tumors. Results of cohorts Q2W-LD and Q3W are included in the current report. The results of the main dose-escalation phase are published elsewhere (To prevent hypersensitivity reactions, patients were premedicated with an oral antihistamine 1 hour prior to receiving tusamitamab ravtansine. Tusamitamab ravtansine was infused at a rate of 2.5 mg/mL for 30 minutes, then at 5 mg/mL thereafter provided there were no signs or symptoms of a hypersensitivity reaction. During the study, the protocol was amended regarding ocular prophylactic measures. Most patients in cohort Q2W-LD received primary ocular prophylaxis with an ophthalmic vasoconstrictor in both eyes before each infusion, corticosteroid preparations for 2 days starting on the day of each infusion, and use of cold masks or pads during each infusion as described previously (